Epigenetics Market

The epigenetics market is projected to reach USD 4.3 billion by 2028 from USD 1.8 billion in 2023, at a CAGR of 18.3 % during the forecast period. Growth in the epigenetics market can be attributed to factors such as growing investment in research & development, declining sequencing cost & time, favorable government initiatives and funding for epigenetics research. Furthermore, technological advancements in epigenetic research and rising demand for epigenetic-based therapeutics are likely to uplift the market growth in coming years.

The epigenetics market is highly competitive. The prominent players operating in this market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories (US), Promega Corporation (US), PerkinElmer (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode (Germany), F. Hoffmann-La Roche Ltd (Switzerland) and among others.The key players of this market are mostly focusing on collaborations, acquisition, partnership, agreement, expansion and advancements in epigenetics technology.

To know about the assumptions considered for the study download the pdf brochure

Illumina Inc (US)

In 2022 Illumina, Inc. (US) held a dominant position in the market. has successfully established a robust customer base encompassing pharmaceutical and biotechnology firms, genomic research centers, and government laboratories and hospitals. Moreover, the company enjoys a monopoly in the NGS market, providing a strategic advantage for venturing into adjacent markets such as epigenetic sequencing. For instance in 2022, Illumina, Inc. entered into an agreement with SomaLogic (US) to introduce SomaScan Proteomics Assay in high throughput next-generation sequencing (NGS) platforms manufactured by Illumina.

Thermofisher Scientific Inc (US)

Thermo Fisher Scientific (US) held the leading position in the market in 2022. The company has Strong brand image along with the diverse product portfolio. For instance in 2022, thermofisher  launched the CE IVD Marked Next Generation Sequencing Instrument designed to be used in in clinical laboratories to perform both diagnostic testing and clinical research on a single instrument.

Merck KgaA (Germany)

Merck KGaA (Germany) is also one of the key player in the epigenetics market. The Life Science Research business segment of the company contributes over 45% to its 2022 revenue by providing a variety of epigenetics assays and kits. These offerings include assays for comprehensive genome-wide DNA methylation assessment as well as targeted evaluation at specific loci.

Related Reports:

Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]